Investigators at Weill Cornell Medicine have developed a versatile and non-toxic technology for controlling the activity of ...

An increasing demand for gene therapies is focusing the industry on enhancing production capabilities, transitioning from ...

Seven years after the first gene-edited babies were revealed, biotech startup Manhattan Genomics is reviving the idea of ...

In a world first, a bespoke gene-editing therapy benefited one child. Now researchers plan to launch a clinical trial of the approach ...

Investigators at Weill Cornell Medicine have developed a versatile and non-toxic technology for controlling the activity of ...

Despite challenges like high costs and regulatory complexities, Europe's vibrant research ecosystem and EMA's supportive ATMP ...

ICHORtec GmbH is pleased to announce an expanded research collaboration with the laboratory of Professor Gregory A. Newby in the Department of Genetic Medicine at the Johns Hopkins University School ...

For decades, synthetic biologists have been developing gene circuits that can be transferred into cells for applications such as reprogramming a stem cell into a neuron or generating a protein that ...

A new West Coast biotech has emerged into the busy in vivo cell therapy space, this time with the backing of Nobel Prize-winning CRISPR pioneer Jennifer Doudna, Ph.D. Azalea Therapeutics has bloomed ...

Scilex Holding Company ("Scilex" or the "Company") (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing and commercializing ...

The biotechnology market is entering a new growth phase, driven by the convergence of genomic science, artificial intelligence, and precision medicine.

The United States Tumor Profiling Market is projected to surge from US$ 3.41 billion in 2024 to US$ 7.44 billion by 2033, ...